STOJSIC, Vladimir et al. Real World Data Survival Outcomes of First Line Immunotherapy with Pembrolizumab in High Expressers with stage IV Non-Small Cell Lung Cancer. Radiology and Oncology, [S. l.], v. 60, n. 3, p. 450–458, 2026. Disponível em: https://radioloncol.com/index.php/ro/article/view/4876. Acesso em: 3 sep. 2026.